| Year |
Citation |
Score |
| 2023 |
Ma W, Xue R, Zhu Z, Farrukh H, Song W, Li T, Zheng L, Pan CX. Increasing cure rates of solid tumors by immune checkpoint inhibitors. Experimental Hematology & Oncology. 12: 10. PMID 36647169 DOI: 10.1186/s40164-023-00372-8 |
0.329 |
|
| 2022 |
Zhu Z, Ma AH, Zhang H, Lin TY, Xue X, Farrukh H, Zhu S, Shi W, Yuan R, Cao Z, Chittepu VCSR, Prabhala R, Li Y, Lam KS, Pan CX. Phototherapy with cancer-specific nanoporphyrin potentiates immunotherapy in bladder cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 35921526 DOI: 10.1158/1078-0432.CCR-22-1362 |
0.303 |
|
| 2022 |
Abd El-Salam MA, Smith CEP, Pan CX. Insights on recent innovations in bladder cancer immunotherapy. Cancer Cytopathology. PMID 35653623 DOI: 10.1002/cncy.22603 |
0.339 |
|
| 2021 |
Parikh M, Liu C, Wu CY, Evans CP, Dall'Era M, Robles D, Lara PN, Agarwal N, Gao AC, Pan CX. Phase Ib trial of reformulated niclosamide with abiraterone/prednisone in men with castration-resistant prostate cancer. Scientific Reports. 11: 6377. PMID 33737681 DOI: 10.1038/s41598-021-85969-x |
0.317 |
|
| 2021 |
Miranda MA, Marcato PD, Mondal A, Chowdhury N, Gebeyehu A, Surapaneni SK, Bentley MVLB, Amaral R, Pan CX, Singh M. Cytotoxic and chemosensitizing effects of glycoalkaloidic extract on 2D and 3D models using RT4 and patient derived xenografts bladder cancer cells. Materials Science & Engineering. C, Materials For Biological Applications. 119: 111460. PMID 33321591 DOI: 10.1016/J.Msec.2020.111460 |
0.36 |
|
| 2020 |
Huang Y, Xue X, Li X, Jia B, Pan CX, Li Y, Lin TY. Novel nanococktail of a dual PI3K/mTOR inhibitor and cabazitaxel for castration-resistant prostate cancer. Advanced Therapeutics. 3. PMID 33072858 DOI: 10.1002/adtp.202000075 |
0.326 |
|
| 2020 |
Candas-Green D, Xie B, Huang J, Fan M, Wang A, Menaa C, Zhang Y, Zhang L, Jing D, Azghadi S, Zhou W, Liu L, Jiang N, Li T, Gao T, ... ... Pan CX, et al. Dual blockade of CD47 and HER2 eliminates radioresistant breast cancer cells. Nature Communications. 11: 4591. PMID 32929084 DOI: 10.1038/S41467-020-18245-7 |
0.342 |
|
| 2020 |
Long Q, Ma AH, Zhang H, Cao Z, Xia R, Lin TY, Sonpavde GP, de Vere White R, Guo J, Pan CX. Combination of cyclin-dependent kinase and immune checkpoint inhibitors for the treatment of bladder cancer. Cancer Immunology, Immunotherapy : Cii. PMID 32506263 DOI: 10.1007/s00262-020-02609-5 |
0.37 |
|
| 2020 |
Amaral R, Zimmermann M, Ma AH, Zhang H, Swiech K, Pan CX. A Simple Three-Dimensional In Vitro Culture Mimicking the In Vivo-Like Cell Behavior of Bladder Patient-Derived Xenograft Models. Cancers. 12. PMID 32455634 DOI: 10.3390/Cancers12051304 |
0.412 |
|
| 2020 |
Pan C, Liu H, Robins E, Song W, Liu D, Li Z, Zheng L. Next-generation immuno-oncology agents: current momentum shifts in cancer immunotherapy. Journal of Hematology & Oncology. 13: 29. PMID 32245497 DOI: 10.1186/s13045-020-00862-w |
0.321 |
|
| 2020 |
Zimmermann M, Li T, Semrad TJ, Wu CY, Yu A, Cimino G, Malfatti M, Haack K, Turteltaub KW, Pan CX, Cho M, Kim EJ, Henderson PT. Oxaliplatin-DNA Adducts as Predictive Biomarkers of FOLFOX Response in Colorectal Cancer: A Potential Treatment Optimization Strategy. Molecular Cancer Therapeutics. PMID 32029633 DOI: 10.1158/1535-7163.MCT-19-0133 |
0.345 |
|
| 2019 |
Palechor-Ceron N, Krawczyk E, Dakic A, Simic V, Yuan H, Blancato J, Wang W, Hubbard F, Zheng YL, Dan H, Strome S, Cullen K, Davidson B, Deeken JF, Choudhury S, ... ... Pan CX, et al. Conditional Reprogramming for Patient-Derived Cancer Models and Next-Generation Living Biobanks. Cells. 8. PMID 31717887 DOI: 10.3390/Cells8111327 |
0.459 |
|
| 2019 |
Martin KA, Hum NR, Sebastian A, He W, Siddiqui S, Ghosh PM, Pan CX, de Vere White R, Loots GG. Methionine Adenosyltransferase 1a (MAT1A) Enhances Cell Survival During Chemotherapy Treatment and is Associated with Drug Resistance in Bladder Cancer PDX Mice. International Journal of Molecular Sciences. 20. PMID 31600961 DOI: 10.3390/Ijms20204983 |
0.48 |
|
| 2019 |
Wei D, Zhang G, Zhu Z, Zheng Y, Yan F, Pan C, Wang Z, Li X, Wang F, Meng P, Zheng W, Yan Z, Zhai D, Lu Z, Yuan J. Nobiletin Inhibits Cell Viability the SRC/AKT/STAT3/YY1AP1 Pathway in Human Renal Carcinoma Cells. Frontiers in Pharmacology. 10: 690. PMID 31354472 DOI: 10.3389/Fphar.2019.00690 |
0.348 |
|
| 2019 |
Mondal AM, Ma AH, Li G, Krawczyk E, Yuan R, Lu J, Schlegel R, Stamatakis L, Kowalczyk KJ, Philips GK, Pan CX, Liu X. Fidelity of a PDX-CR model for bladder cancer. Biochemical and Biophysical Research Communications. PMID 31303270 DOI: 10.1016/J.Bbrc.2019.06.165 |
0.38 |
|
| 2019 |
Malfatti MA, Buchholz BA, Enright HA, Stewart BJ, Ognibene TJ, McCartt AD, Loots GG, Zimmermann M, Scharadin TM, Cimino GD, Jonas BA, Pan CX, Bench G, Henderson PT, Turteltaub KW. Radiocarbon Tracers in Toxicology and Medicine: Recent Advances in Technology and Science. Toxics. 7. PMID 31075884 DOI: 10.3390/Toxics7020027 |
0.307 |
|
| 2019 |
Lin TY, Zhu Y, Li Y, Zhang H, Ma AH, Long Q, Keck J, Lam KS, Pan CX, Jonas BA. Daunorubicin-containing CLL1-targeting nanomicelles have anti-leukemia stem cell activity in acute myeloid leukemia. Nanomedicine : Nanotechnology, Biology, and Medicine. PMID 31055076 DOI: 10.1016/J.Nano.2019.04.007 |
0.34 |
|
| 2019 |
Dall'era M, Evans CP, Pan C, Parikh M, Lara P, McPherson J. Are prostate cancer patients with BRCA1 and BRCA2 mutations safe for active surveillance? Journal of Clinical Oncology. 37: 19-19. DOI: 10.1200/Jco.2019.37.7_Suppl.19 |
0.388 |
|
| 2019 |
Parikh M, Robles D, Pan C, Lara P, Yang JC, Gao A, Evans CP. Results from a phase Ib/II study of enzalutamide and metformin in men with castration resistant prostate cancer (CRPC). Journal of Clinical Oncology. 37: 5054-5054. DOI: 10.1200/Jco.2019.37.15_Suppl.5054 |
0.406 |
|
| 2019 |
Sampson E, Nikolov K, Henderson PT, Apfel C, Pan C, Zimmermann M, Ma A. PDX validation of a 3D microtumor platform. Journal of Clinical Oncology. 37: 3029-3029. DOI: 10.1200/Jco.2019.37.15_Suppl.3029 |
0.404 |
|
| 2019 |
Chen J, Cho M, Zimmermann M, Semrad T, Wu C, Yu A, Pan C, Henderson PT, Kim EJ. Abstract CT055: Microdose induced oxaliplatin-DNA adducts as a predictive biomarker of response in colorectal cancer Cancer Research. 79. DOI: 10.1158/1538-7445.Am2019-Ct055 |
0.449 |
|
| 2019 |
Pan C, Zhang H, Ma A, Zeng S, Zimmermann M, Tepper C, Henderson P, Carvajal-Carmona L, Gandour-Edwards R, Chen M, Airhart S, Whtie RdV. Abstract 1067: A patient-derived xenograft (PDX) platform for cancer translational, precision medicine and health disparity research Cancer Research. 79: 1067-1067. DOI: 10.1158/1538-7445.Am2019-1067 |
0.434 |
|
| 2018 |
Wang S, Scharadin TM, Zimmermann M, Malfatti MA, Turteltaub KW, de Vere White R, Pan CX, Henderson PT. Correlation of platinum cytotoxicity to drug-DNA adduct levels in a breast cancer cell line panel. Chemical Research in Toxicology. PMID 30381944 DOI: 10.1021/acs.chemrestox.8b00170 |
0.318 |
|
| 2018 |
Parikh M, Pan CX, Beckett LA, Li Y, Robles DA, Aujla PK, Lara PN. Pembrolizumab Combined With Either Docetaxel or Gemcitabine in Patients With Advanced or Metastatic Platinum-Refractory Urothelial Cancer: Results From a Phase I Study. Clinical Genitourinary Cancer. PMID 30166228 DOI: 10.1016/J.Clgc.2018.07.004 |
0.424 |
|
| 2018 |
Scharadin TM, Malfatti MA, Haack K, Turteltaub KW, Pan CX, Henderson PT, Jonas BA. Towards predicting AML patient response to 7+3 induction chemotherapy via diagnostic microdosing. Chemical Research in Toxicology. PMID 30152692 DOI: 10.1021/Acs.Chemrestox.8B00107 |
0.406 |
|
| 2018 |
Long Q, Lin TY, Huang Y, Li X, Ma AH, Zhang H, Carney R, Airhart S, Lam KS, Pan CX, Li Y. Imaging-guided photo-therapeutic nanoporphyrin synergized HSP90 inhibitor in patient-derived xenograft bladder cancer model. Nanomedicine : Nanotechnology, Biology, and Medicine. PMID 29317342 DOI: 10.1016/J.Nano.2017.12.014 |
0.434 |
|
| 2018 |
D'Abronzo LS, Pan CX, Ghosh PM. Evaluation of Protein Levels of the Receptor Tyrosine Kinase ErbB3 in Serum. Methods in Molecular Biology (Clifton, N.J.). 1655: 319-334. PMID 28889394 DOI: 10.1007/978-1-4939-7234-0_22 |
0.334 |
|
| 2018 |
Pan C, Lara P, Evans CP, Parikh M, White RdV, Dall'era M, Liu C, Robles D, Gao A. A phase Ib/II trial of indomethacin and enzalutamide to treat castration-resistant prostate cancer (CRPC). Journal of Clinical Oncology. 36. DOI: 10.1200/Jco.2018.36.6_Suppl.Tps394 |
0.445 |
|
| 2018 |
Lara P, Parikh M, Robles D, Lara F, Meyers FJ, Pan C. Pilot trial of ibrutinib plus nivolumab in patients (pts) with metastatic renal cell cancer (mRCC): Results from a dose-finding cohort. Journal of Clinical Oncology. 36: 4580-4580. DOI: 10.1200/Jco.2018.36.6_Suppl.600 |
0.372 |
|
| 2018 |
Parikh M, Pan C, Beckett L, Li Y, Robles D, DeVisser C, Lara P. Combination checkpoint immunotherapy and cytotoxic chemotherapy: Further results from a phase Ib/II trial of pembrolizumab and docetaxel or gemcitabine in patients with advanced or metastatic urothelial cancer. Journal of Clinical Oncology. 36: 525-525. DOI: 10.1200/Jco.2018.36.6_Suppl.525 |
0.373 |
|
| 2018 |
Parikh M, Hyunh JC, Lara P, Pan C, Robles D, Evans CP. Enzalutamide and metformin combination therapy to overcome autophagy resistance in castration resistant prostate cancer (CRPC): Current results from a phase I study. Journal of Clinical Oncology. 36: 281-281. DOI: 10.1200/Jco.2018.36.6_Suppl.281 |
0.386 |
|
| 2018 |
Pan C, Lara P, Evans CP, Parikh M, Dall'era M, Liu C, Robles D, Gao A. Niclosamide in combination with abiraterone and prednisone in men with castration-resistant prostate cancer (CRPC): initial results from a phase Ib/II trial. Journal of Clinical Oncology. 36: 192-192. DOI: 10.1200/Jco.2018.36.6_Suppl.192 |
0.403 |
|
| 2018 |
Pan C, Lara P, Evans CP, Parikh M, Dall'era M, Liu C, Robles D, Gao A. Combination of niclosamide to target androgen receptor variant 7 (AR-V7) and abiraterone to target androgen synthesis for the treatment of castration-resistant prostate cancer (CRPC): Initial results from a phase Ib/II trial. Journal of Clinical Oncology. 36: 5031-5031. DOI: 10.1200/Jco.2018.36.15_Suppl.5031 |
0.362 |
|
| 2018 |
Liu C, Lou W, Pan C, Lara P, Evans C, Parikh M, White Rd, Dall'Era M, Gao A. Mp52-01 Combination Of Indomethacin And Enzalutamide To Treat Castration-Resistant Prostate Cancer The Journal of Urology. 199. DOI: 10.1016/J.Juro.2018.02.1652 |
0.416 |
|
| 2017 |
Wang F, Zhang H, Ma AH, Yu W, Zimmermann M, Yang J, Hwang SH, Zhu D, Lin TY, Malfatti M, Turteltaub KW, Henderson PT, Airhart S, Hammock BD, Yuan J, ... ... Pan CX, et al. COX-2/sEH Dual Inhibitor PTUPB Potentiates the Anti-tumor Efficacy of Cisplatin. Molecular Cancer Therapeutics. PMID 29284644 DOI: 10.1158/1535-7163.Mct-16-0818 |
0.423 |
|
| 2017 |
Wang M, Yao LC, Cheng M, Cai D, Martinek J, Pan CX, Shi W, Ma AH, De Vere White RW, Airhart S, Liu ET, Banchereau J, Brehm MA, Greiner DL, Shultz LD, et al. Humanized mice in studying efficacy and mechanisms of PD-1-targeted cancer immunotherapy. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. PMID 29146734 DOI: 10.1096/Fj.201700740R |
0.379 |
|
| 2017 |
Gheibi P, Zeng S, Son KJ, Vu T, Ma AH, Dall'Era MA, Yap SA, de Vere White RW, Pan CX, Revzin A. Microchamber Cultures of Bladder Cancer: A Platform for Characterizing Drug Responsiveness and Resistance in PDX and Primary Cancer Cells. Scientific Reports. 7: 12277. PMID 28947782 DOI: 10.1038/S41598-017-12543-9 |
0.355 |
|
| 2017 |
Zeng S, Zhu Y, Ma AH, Yu W, Zhang H, Lin TY, Shi W, Tepper CG, Henderson PT, Airhart S, Guo J, Xu C, de Vere White R, Pan CX. The Phosphatidylinositol 3-kinase Pathway as a Potential Therapeutic Target in Bladder Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28808038 DOI: 10.1158/1078-0432.Ccr-17-0033 |
0.377 |
|
| 2017 |
Liu C, Armstrong CM, Lou W, Lombard AP, Cucchiara V, Gu X, Yang JC, Nadiminty N, Pan CX, Evans CP, Gao AC. Niclosamide and bicalutamide combination treatment overcomes enzalutamide and bicalutamide resistant prostate cancer. Molecular Cancer Therapeutics. PMID 28500234 DOI: 10.1158/1535-7163.Mct-16-0912 |
0.378 |
|
| 2017 |
Wang SS, Zimmermann M, Zhang H, Lin TY, Malfatti M, Haack K, Turteltaub KW, Cimino GD, de Vere White R, Pan CX, Henderson PT. A Diagnostic Microdosing Approach to Investigate Platinum Sensitivity in Non-Small Cell Lung Cancer. International Journal of Cancer. PMID 28437852 DOI: 10.1002/Ijc.30747 |
0.41 |
|
| 2017 |
Lara P, Beckett L, Li Y, Parikh M, Robles D, Aujla P, Pan C. Combination checkpoint immunotherapy and cytotoxic chemotherapy: Pembrolizumab (Pembro) plus either docetaxel or gemcitabine in patients with advanced or metastatic urothelial cancer. Journal of Clinical Oncology. 35: 398-398. DOI: 10.1200/Jco.2017.35.6_Suppl.398 |
0.374 |
|
| 2017 |
Pan C, Shi W, Ma A, Zhang H, Lara P, Keck JG, Palucka K, Airhart SD, White Rd. Humanized mice (humice) carrying patient-derived xenograft (PDX) as a platform to develop immunotherapy in bladder cancer (BCa). Journal of Clinical Oncology. 35: 381-381. DOI: 10.1200/Jco.2017.35.6_Suppl.381 |
0.32 |
|
| 2017 |
Pan C, Liu C, Lara P, Evans CP, Dall'Era M, Yap S, Lou W, Gao A. Indomethacin to inhibit AKR1C3 intracrine androgen production and sensitizes prostate cancer (PCa) to enzalutamide. Journal of Clinical Oncology. 35: 161-161. DOI: 10.1200/Jco.2017.35.6_Suppl.161 |
0.392 |
|
| 2017 |
Candas D, Zhang L, Menaa C, Fan M, Zhang Y, Liu L, Zhou W, Azghadi S, Sweeney C, Shen R, Lin T, Pan C, Vaughan AT, Wang JM, Chen H, et al. Abstract LB-226: Dual inhibition of CD47 and HER2 to radiosensitize breast cancer cells Cancer Research. 77. DOI: 10.1158/1538-7445.Am2017-Lb-226 |
0.341 |
|
| 2017 |
Martin KA, Hum NR, Sebastian A, Murugesh DK, Pan C, Ma A, White RdV, Loots G. Abstract 97: RNA sequencing of bladder cancer patient-derived xenograft models identifies genes associated with chemoresistance Cancer Research. 77: 97-97. DOI: 10.1158/1538-7445.Am2017-97 |
0.339 |
|
| 2017 |
Liu C, Lou W, Yang J, Pan C, Lara P, Evans C, Gao A. Pd37-12 Evaluation Of Niclosamide As A Potent Inhibitor Of Androgen Receptor Variants To Overcome Resistance To Abiraterone And Enzalutamide In Advanced Prostate Cancer The Journal of Urology. 197. DOI: 10.1016/J.Juro.2017.02.1574 |
0.376 |
|
| 2016 |
Zimmermann M, Wang SS, Zhang H, Lin TY, Malfatti M, Haack K, Ognibene T, Yang H, Airhart S, Turteltaub KW, Cimino GD, Tepper CG, Drakaki A, Chamie K, de Vere White R, ... Pan CX, et al. Microdose-induced Drug-DNA Adducts as Biomarkers of Chemotherapy Resistance in Humans and Mice. Molecular Cancer Therapeutics. PMID 27903751 DOI: 10.1158/1535-7163.Mct-16-0381 |
0.404 |
|
| 2016 |
Scharadin TM, Zhang H, Zimmermann M, Wang S, Malfatti MA, Cimino GD, Turteltaub KW, de Vere White RW, Pan CX, Henderson PT. A diagnostic microdosing approach to study gemcitabine resistance. Chemical Research in Toxicology. PMID 27657672 DOI: 10.1021/Acs.Chemrestox.6B00247 |
0.372 |
|
| 2016 |
Pan A, Zhang H, Li Y, Lin TY, Wang F, Lee J, Cheng M, Dall'Era M, Li T, deVere White R, Pan CX, Lam KS. Disulfide-crosslinked nanomicelles confer cancer-specific drug delivery and improve efficacy of paclitaxel in bladder cancer. Nanotechnology. 27: 425103. PMID 27640312 DOI: 10.1088/0957-4484/27/42/425103 |
0.436 |
|
| 2016 |
Yi X, Zhang J, Yan F, Lu Z, Huang J, Pan C, Yuan J, Zheng W, Zhang K, Wei D, He W, Yuan J. Synthesis of IR-780 dye-conjugated abiraterone for prostate cancer imaging and therapy. International Journal of Oncology. PMID 27633959 DOI: 10.3892/Ijo.2016.3693 |
0.448 |
|
| 2016 |
Lin TY, Li Y, Liu Q, Chen JL, Zhang H, Lac D, Zhang H, Ferrara KW, Wachsmann-Hogiu S, Li T, Airhart S, deVere White R, Lam KS, Pan CX. Novel theranostic nanoporphyrins for photodynamic diagnosis and trimodal therapy for bladder cancer. Biomaterials. 104: 339-351. PMID 27479049 DOI: 10.1016/J.Biomaterials.2016.07.026 |
0.356 |
|
| 2016 |
Lin TY, Guo W, Long Q, Ma A, Liu Q, Zhang H, Huang Y, Chandrasekaran S, Pan C, Lam KS, Li Y. HSP90 Inhibitor Encapsulated Photo-Theranostic Nanoparticles for Synergistic Combination Cancer Therapy. Theranostics. 6: 1324-1335. PMID 27375782 DOI: 10.7150/Thno.14882 |
0.446 |
|
| 2016 |
Lara J, Brunson A, Keegan TH, Malogolowkin M, Pan CX, Yap S, deVere White R. Determinants of survival in adolescents and young adults with urothelial bladder cancer: results from the California Cancer Registry. The Journal of Urology. PMID 27208515 DOI: 10.1016/J.Juro.2016.05.082 |
0.327 |
|
| 2016 |
Chow H, Ghosh PM, deVere White R, Evans CP, Dall'Era MA, Yap SA, Li Y, Beckett LA, Lara PN, Pan CX. A phase 2 clinical trial of everolimus plus bicalutamide for castration-resistant prostate cancer. Cancer. PMID 27019001 DOI: 10.1002/Cncr.29927 |
0.433 |
|
| 2016 |
Wang S, Zhang H, Scharadin TM, Zimmermann M, Hu B, Pan AW, Vinall R, Lin TY, Cimino G, Chain P, Vuyisich M, Gleasner C, Mcmurry K, Malfatti M, Turteltaub K, ... ... Pan CX, et al. Molecular Dissection of Induced Platinum Resistance through Functional and Gene Expression Analysis in a Cell Culture Model of Bladder Cancer. Plos One. 11: e0146256. PMID 26799320 DOI: 10.1371/Journal.Pone.0146256 |
0.432 |
|
| 2016 |
Sonpavde G, Rosser CJ, Pan C, Parikh RA, Nix J, Gingrich JR, Hernandez L, Huang B, Wong HC. Phase I trial of ALT-801, a first-in-class T-cell receptor (TCR)-interleukin (IL)-2 fusion molecule, plus gemcitabine (G) for Bacillus Calmette Guerin (BCG)-resistant non-muscle-invasive bladder cancer (NMIBC). Journal of Clinical Oncology. 34: 451-451. DOI: 10.1200/Jco.2016.34.2_Suppl.451 |
0.32 |
|
| 2016 |
Lara P, Brunson A, White Rd, Dall'Era MA, Evans CP, Yap SA, Meyers FJ, Pan C. Survival of patients (pts) with metastatic bladder cancer (MBC) in the past quarter century: Sobering results from the California Cancer Registry (CCR). Journal of Clinical Oncology. 34. DOI: 10.1200/Jco.2016.34.15_Suppl.E16033 |
0.308 |
|
| 2016 |
Lara P, Heilmann A, Elvin JA, White Rd, Gandour-Edwards R, Evans CP, Pan C, Ross JS, Stephens PJ, Miller VA, Ali SM. TMPRSS-ERG fusion in men with prostate cancer (PCa) and non-prostate malignancies: Defining a role for comprehensive genomic profiling (CGP) to guide clinical care. Journal of Clinical Oncology. 34: 5037-5037. DOI: 10.1200/Jco.2016.34.15_Suppl.5037 |
0.414 |
|
| 2016 |
Sebastian A, Martin KA, Pan C, Ma A, White RWd, Loots GG. Abstract 2106: Transcriptome analysis of patient-derived bladder cancer xenografts identifies genes associated with chemoresistance Cancer Research. 76: 2106-2106. DOI: 10.1158/1538-7445.Am2016-2106 |
0.379 |
|
| 2016 |
Li Y, Lin T, Pan C, Lam KS. Abstract 1344: Novel targeting all-in-one nanoporphyrin platform against bladder cancer Cancer Research. 76: 1344-1344. DOI: 10.1158/1538-7445.Am2016-1344 |
0.438 |
|
| 2016 |
Lin T, Li Y, Zhu Y, Zhang H, Harse R, Lam K, Jonas B, Pan C. Abstract 1313: Targeting micelles eradicate acute myeloid leukemia stem cells in a patient-derived leukemia xenograft model Cancer Research. 76: 1313-1313. DOI: 10.1158/1538-7445.Am2016-1313 |
0.352 |
|
| 2015 |
Jiang S, Pan AW, Lin TY, Zhang H, Malfatti MA, Turteltaub KW, Henderson P, Pan CX. Paclitaxel enhances Carboplatin-DNA adduct formation and cytotoxicity. Chemical Research in Toxicology. PMID 26544157 DOI: 10.1021/Acs.Chemrestox.5B00422 |
0.317 |
|
| 2015 |
Pan CX, Zhang H, Tepper CG, Lin TY, Davis RR, Keck J, Ghosh PM, Gill P, Airhart S, Bult C, Gandara DR, Liu E, de Vere White RW. Development and Characterization of Bladder Cancer Patient-Derived Xenografts for Molecularly Guided Targeted Therapy. Plos One. 10: e0134346. PMID 26270481 DOI: 10.1371/Journal.Pone.0134346 |
0.438 |
|
| 2015 |
Tomlinson B, Lin TY, Dall'Era M, Pan CX. Nanotechnology in bladder cancer: current state of development and clinical practice. Nanomedicine (London, England). 10: 1189-201. PMID 25929573 DOI: 10.2217/Nnm.14.212 |
0.418 |
|
| 2015 |
Gandara DR, Mack PC, Bult C, Li T, Lara PN, Riess JW, Astrow SH, Gandour-Edwards R, Cooke DT, Yoneda KY, Moore EH, Pan CX, Burich RA, David EA, Keck JG, et al. Bridging tumor genomics to patient outcomes through an integrated patient-derived xenograft platform. Clinical Lung Cancer. 16: 165-72. PMID 25838158 DOI: 10.1016/J.Cllc.2015.03.001 |
0.441 |
|
| 2015 |
Tomlinson BK, Thomson JA, Bomalaski JS, Diaz M, Akande T, Mahaffey N, Li T, Dutia MP, Kelly K, Gong IY, Semrad T, Gandara DR, Pan CX, Lara PN. Phase I Trial of Arginine Deprivation Therapy with ADI-PEG 20 Plus Docetaxel in Patients with Advanced Malignant Solid Tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 2480-6. PMID 25739672 DOI: 10.1158/1078-0432.Ccr-14-2610 |
0.332 |
|
| 2015 |
Lo EN, Beckett LA, Pan CX, Robles D, Suga JM, Sands JM, Lara PN. Prospective evaluation of low-dose ketoconazole plus hydrocortisone in docetaxel pre-treated castration-resistant prostate cancer patients. Prostate Cancer and Prostatic Diseases. 18: 144-8. PMID 25667107 DOI: 10.1038/Pcan.2015.2 |
0.425 |
|
| 2015 |
Chow H, Wang S, Zhang H, Zimmermann M, Lin T, Scharadin T, Malfatti M, Evans CP, Cimino G, Turteltaub K, de Vere White R, Henderson PT, Pan C. A microdosing study to identify chemoresistance in bladder cancer. Journal of Clinical Oncology. 33: 356-356. DOI: 10.1200/Jco.2015.33.7_Suppl.356 |
0.416 |
|
| 2015 |
Pan C, Lin T, Zhang H, Li Y, Airhart SD, White Rd, Lam KS. Cancer-specific nanotheranostics to improve the diagnosis and treatment of bladder cancer. Journal of Clinical Oncology. 33: 323-323. DOI: 10.1200/Jco.2015.33.7_Suppl.323 |
0.453 |
|
| 2015 |
Pan C, Zhang H, Lin T, Tepper C, Keck J, Ghosh P, Airhart SD, Bult CJ, Gandara DR, Evans CP, Liu ET, deVere White R. Patient-derived xenograft platform to guide precision medicine in bladder cancer. Journal of Clinical Oncology. 33: 315-315. DOI: 10.1200/Jco.2015.33.7_Suppl.315 |
0.467 |
|
| 2015 |
Chow H, Ghosh P, D'Abronzo LS, White RdV, Dall'Era M, Evans CP, Yap SA, Lara P, Pan C. Everolimus plus bicalutamide for castration resistant prostate cancer (CRPC): Bench to bedside and back. Journal of Clinical Oncology. 33: 189-189. DOI: 10.1200/Jco.2015.33.7_Suppl.189 |
0.414 |
|
| 2015 |
Tomlinson BK, Bomalaski JS, Diaz M, Akande T, Li T, Semrad TJ, Kelly K, Gandara DR, Pan C, Lara P. ADI-PEG 20 plus docetaxel (DOC) in men with castrate resistant prostate cancer (CRPC): Results from a phase Ib trial. Journal of Clinical Oncology. 33. DOI: 10.1200/Jco.2015.33.15_Suppl.E16116 |
0.386 |
|
| 2015 |
Lara JD, Brunson A, White RdV, Pan C, Yap SA, Balagtas JR. Determinants of survival in adolescents and young adults with urothelial cancer: Results from the California Cancer Registry. Journal of Clinical Oncology. 33. DOI: 10.1200/Jco.2015.33.15_Suppl.E15543 |
0.376 |
|
| 2015 |
Pan AW, Zhang H, Lin T, Li Y, Li T, Keck J, Tepper C, Airhart SD, Liu ET, Pan C, de Vere White R, Lam KS. Patient-derived bladder cancer xenografts as a platform for drug development in bladder cancer. Journal of Clinical Oncology. 33: e15528-e15528. DOI: 10.1200/Jco.2015.33.15_Suppl.E15528 |
0.462 |
|
| 2015 |
Pan C, Zhang H, Lin T, Tepper C, Keck J, Ghosh P, Airhart SD, Carvajal-Carmona L, Bult CJ, Gandara DR, Liu ET, de Vere White R. Development and characterization of patient-derived xenografts to guide precision medicine in bladder cancer. Journal of Clinical Oncology. 33: e15522-e15522. DOI: 10.1200/Jco.2015.33.15_Suppl.E15522 |
0.387 |
|
| 2015 |
Williamson JB, Zhang H, Lott P, Sahasrabudhe R, Soares S, Airhart S, Tepper C, Pan C, DeVere-White R, Carvajal-Carmona L. Abstract 4820: A comparison of bulk versus single-cell whole-exome sequencing to study cancer genetic heterogeneity Cancer Research. 75: 4820-4820. DOI: 10.1158/1538-7445.Am2015-4820 |
0.397 |
|
| 2015 |
Li Y, Lin C, Pan C, Lam KS. From combinatorial chemistry to targeting nano-phototherapeutic agents Photodiagnosis and Photodynamic Therapy. 12: 368. DOI: 10.1016/J.Pdpdt.2015.07.167 |
0.368 |
|
| 2014 |
Li X, Choi WW, Yan R, Yu H, Krasnoperov V, Kumar SR, Schuckman A, Klumpp DJ, Pan CX, Quinn D, Gill IS, Gill PS, Liu R. The differential expression of EphB2 and EphB4 receptor kinases in normal bladder and in transitional cell carcinoma of the bladder. Plos One. 9: e105326. PMID 25148033 DOI: 10.1371/Journal.Pone.0105326 |
0.365 |
|
| 2014 |
Lo EN, Beckett LA, Pan C, Robles D, Suga JM, Sands J, Lara P. Prospective evaluation of low-dose ketoconazole plus hydrocortisone (HC) in chemotherapy-pretreated castration-resistant prostate cancer (CRPC) patients. Journal of Clinical Oncology. 32: 227-227. DOI: 10.1200/Jco.2014.32.4_Suppl.227 |
0.376 |
|
| 2014 |
Pan C, Chow H, Ghosh P, White Rd, Evans CP, Dall'Era MA, Yap SA, Li J, Beckett LA, Lara P. Everolimus plus bicalutamide in men with castration-resistant prostate cancer (CRPC): Final results of a phase II trial. Journal of Clinical Oncology. 32: 5028-5028. DOI: 10.1200/Jco.2014.32.15_Suppl.5028 |
0.435 |
|
| 2014 |
Pan C, Zhang H, Tepper C, Ghosh P, Kuslak-Meyer S, Airhart SD, Gandara DR, Liu ET, White Rd. A patient-derived xenograft (PDX) platform to optimize omics-driven precision medicine in bladder cancer. Journal of Clinical Oncology. 32: 4536-4536. DOI: 10.1200/Jco.2014.32.15_Suppl.4536 |
0.404 |
|
| 2014 |
Pan C, Zhang H, Tepper C, Ghosh P, Kuslak-Meyer S, Airhart S, Gill P, Gandara D, Liu E, White RdV. Abstract LB-32: Patient-derived xenograft (PDX) paraclinical platform to guide precision medicine in urothelial cancer Cancer Research. 74. DOI: 10.1158/1538-7445.Am2014-Lb-32 |
0.457 |
|
| 2014 |
Pan AW, Wang S, Zhang H, Vinall R, Lin T, Malfatti M, Zimmermann M, Scharadin T, Turteltaub K, White RdV, Pan C, Henderson P. Abstract 905: Molecular dissection of platinum resistance through functional analysis Cancer Research. 74: 905-905. DOI: 10.1158/1538-7445.Am2014-905 |
0.466 |
|
| 2014 |
Zimmermann M, Scharadin TM, Zhang H, Lin T, White RWd, Pan C, Henderson PT. Abstract 2821: Dual-label microdosing approach to identify chemoresistance to carboplatin and gemcitabine combination chemotherapy Cancer Research. 74: 2821-2821. DOI: 10.1158/1538-7445.Am2014-2821 |
0.469 |
|
| 2013 |
Pai A, Brunson A, Brown M, Pan C, Lara PN. Evolving Epidemiologic Trends in Nonclear Cell Renal Cell Cancer: An Analysis of the California Cancer Registry Urology. 82: 840-845. PMID 24074980 DOI: 10.1016/J.Urology.2013.07.020 |
0.405 |
|
| 2013 |
Cimino GD, Pan CX, Henderson PT. Personalized medicine for targeted and platinum-based chemotherapy of lung and bladder cancer. Bioanalysis. 5: 369-91. PMID 23394702 DOI: 10.4155/Bio.12.325 |
0.441 |
|
| 2013 |
Lin TY, Li YP, Zhang H, Luo J, Goodwin N, Gao T, White Rde V, Lam KS, Pan CX. Tumor-targeting multifunctional micelles for imaging and chemotherapy of advanced bladder cancer. Nanomedicine (London, England). 8: 1239-51. PMID 23199207 DOI: 10.2217/Nnm.12.150 |
0.451 |
|
| 2013 |
Tomlinson BK, Bomalaski JS, Diaz M, Akande T, Mahaffey N, Li T, Dutia MP, Kelly K, Gong I, Gandara DR, Pan C, Lara P. Phase I trial of ADI-peg 20 plus docetaxel (DOC) in patients (pts) with advanced solid tumors. Journal of Clinical Oncology. 31: 2569-2569. DOI: 10.1200/Jco.2013.31.15_Suppl.2569 |
0.332 |
|
| 2013 |
Lam KS, Li Y, Lin T, Zhang H, Feng C, Luo Y, Pan C, Xiao K, Xiao W, Lee J, Liu R. Abstract 4508: Novel multifunctional nanocarriers for drug delivery, photodynamic therapy, sonodynamic therapy, MRI and PET imaging. Cancer Research. 73: 4508-4508. DOI: 10.1158/1538-7445.Am2013-4508 |
0.39 |
|
| 2013 |
Pan C, Wang S, He M, Li T, Lin T, Zhang H, Malfatti M, Gandara D, Li T, Yoneda K, Lee J, Dall'Era M, Cimino G, White RdV, Turteltaub K, et al. Abstract 1183: Phase 0 microdosing trial quantitating DNA adduct formation to identify platinum chemosensitivity: from bench to bedside. Cancer Research. 73: 1183-1183. DOI: 10.1158/1538-7445.Am2013-1183 |
0.423 |
|
| 2013 |
Pan AW, Lin T, Zhang H, Goodwin N, Pan C, Li Y, Lam K. Abstract A80: Cancer-specific targeting nanomicelles for diagnosis and treatment of bladder cancer. Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-A80 |
0.457 |
|
| 2012 |
Pai AP, Hillegonds D, Lara P, Pan CX, Shelton D. Calcium metabolism in patients with castration-resistant prostate cancer: Development of a quantitative urinary assay for extent of bone metastasis. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 130. PMID 27968179 DOI: 10.1200/Jco.2012.30.5_Suppl.130 |
0.359 |
|
| 2012 |
Lin TY, Zhang H, Luo J, Li Y, Gao T, Lara PN, de Vere White R, Lam KS, Pan CX. Multifunctional targeting micelle nanocarriers with both imaging and therapeutic potential for bladder cancer. International Journal of Nanomedicine. 7: 2793-804. PMID 22745542 DOI: 10.2147/Ijn.S27734 |
0.42 |
|
| 2012 |
Chang JS, Lara PN, Pan C. Progress in Personalizing Chemotherapy for Bladder Cancer Advances in Urology. 2012: 364919-364919. PMID 22400017 DOI: 10.1155/2012/364919 |
0.453 |
|
| 2012 |
Shek D, Tomlinson B, Brown M, Brunson A, Pan CX, Lara PN. Epidemiologic trends in renal cell carcinoma in the cytokine and post-cytokine eras: A registry analysis of 28,252 patients Clinical Genitourinary Cancer. 10: 93-98. PMID 22382008 DOI: 10.1016/J.Clgc.2012.01.007 |
0.367 |
|
| 2012 |
Zhang H, Aina OH, Lam KS, de Vere White R, Evans C, Henderson P, Lara PN, Wang X, Bassuk JA, Pan CX. Identification of a bladder cancer-specific ligand using a combinatorial chemistry approach. Urologic Oncology. 30: 635-45. PMID 20888272 DOI: 10.1016/J.Urolonc.2010.06.011 |
0.353 |
|
| 2012 |
Pai AP, Brown M, Pan C, Lara P. Evolving trends in non-clear cell renal cell cancer (RCC) epidemiology: A large registry analysis of 4,483 patients. Journal of Clinical Oncology. 30: 4607-4607. DOI: 10.1200/Jco.2012.30.15_Suppl.4607 |
0.409 |
|
| 2012 |
Pan C, Robles D, D'Abronzo L, Beggs RE, deVere-White R, Lara P, Ghosh PM. Abstract 5750: Synergistic effects of everolimus and bicalutamide in castration-resistant prostate cancer: Results from a phase I/II clinical trial Cancer Research. 72: 5750-5750. DOI: 10.1158/1538-7445.Am2012-5750 |
0.442 |
|
| 2012 |
Lin T, Luo J, Zhang H, Li Y, Gao T, Whtie RdV, Lam KS, Pan C. Abstract 378: Multifunctional bladder cancer targeting micelle nanocarriers with both imaging and therapeutic potentials Cancer Research. 72: 378-378. DOI: 10.1158/1538-7445.Am2012-378 |
0.425 |
|
| 2012 |
Trehan S, Lin T, Liu R, Zhang H, Pan C. Abstract 367: Imaging and diagnostic potentials of a novel cancer targeting peptide on bladder cancerin vitroandin vivo Cancer Research. 72: 367-367. DOI: 10.1158/1538-7445.Am2012-367 |
0.428 |
|
| 2012 |
Zhang H, Luo J, Li Y, Henderson PT, Wang Y, Wachsmann-Hogiu S, Lam KS, Pan C. Abstract 3488: Targeting ligands and nanotherapeutics against acute myeloid leukemia stem cell Cancer Research. 72: 3488-3488. DOI: 10.1158/1538-7445.Am2012-3488 |
0.367 |
|
| 2011 |
Pai AP, Lara P, Pan C, Hillegonds D. Direct measurement of calcium metabolism in patients with castration-resistant prostate cancer using a novel isotope tracing approach in urine. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: e15083. PMID 28020431 DOI: 10.1200/Jco.2011.29.15_Suppl.E15083 |
0.397 |
|
| 2011 |
Pan C, Ghosh P, Lara P, Robles D, Beckett L, de Vere White R. Encouraging activity of bicalutamide and everolimus in castration-resistant prostate cancer (CRPC): Early results from a phase II clinical trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 157. PMID 27968572 DOI: 10.1200/Jco.2010.28.15_Suppl.E15131 |
0.388 |
|
| 2011 |
Cheng L, Alexander R, Zhang S, Pan CX, MacLennan GT, Lopez-Beltran A, Montironi R. The clinical and therapeutic implications of cancer stem cell biology. Expert Review of Anticancer Therapy. 11: 1131-43. PMID 21806335 DOI: 10.1586/era.11.82 |
0.354 |
|
| 2011 |
Lin TY, Zhang H, Wang S, Xie L, Li B, Rodriguez CO, de Vere White R, Pan CX. Targeting canine bladder transitional cell carcinoma with a human bladder cancer-specific ligand. Molecular Cancer. 10: 9. PMID 21272294 DOI: 10.1186/1476-4598-10-9 |
0.409 |
|
| 2011 |
Henderson PT, Li T, He M, Zhang H, Malfatti M, Gandara D, Grimminger PP, Danenberg KD, Beckett L, de Vere White RW, Turteltaub KW, Pan CX. A microdosing approach for characterizing formation and repair of carboplatin-DNA monoadducts and chemoresistance. International Journal of Cancer. 129: 1425-34. PMID 21128223 DOI: 10.1002/Ijc.25814 |
0.381 |
|
| 2011 |
Pan C, Wang S, White RdV, Lara P, Gandara D, Mack P, Li T, Turteltaub K, Henderson P. Abstract LB-403: A Phase 0 microdosing clinical trial to identify chemoresistance Cancer Research. 71. DOI: 10.1158/1538-7445.Am2011-Lb-403 |
0.431 |
|
| 2010 |
Wang S, Zhang H, Malfatti M, de Vere White R, Lara PN, Turteltaub K, Henderson P, Pan CX. Gemcitabine causes minimal modulation of carboplatin-DNA monoadduct formation and repair in bladder cancer cells. Chemical Research in Toxicology. 23: 1653-5. PMID 21028869 DOI: 10.1021/Tx1003547 |
0.386 |
|
| 2010 |
Sandhu R, Pan CX, Wun T, Harvey D, Zhou H, White RH, Chew HK. The incidence of venous thromboembolism and its effect on survival among patients with primary bladder cancer. Cancer. 116: 2596-603. PMID 20336780 DOI: 10.1002/Cncr.25004 |
0.413 |
|
| 2010 |
Shek DW, Brown M, Pan C, Lara P. Epidemiological trends in renal cell carcinoma (RCC) in the cytokine (CYT) and targeted therapy (TT) eras: A registry analysis of 28,252 patients (pts). Journal of Clinical Oncology. 28: 4598-4598. DOI: 10.1200/Jco.2010.28.15_Suppl.4598 |
0.351 |
|
| 2010 |
Zhang H, Wang Y, Ghosh P, Lara PN, Pasquinelli P, Beckett L, White RWd, Pan C. Abstract 3720: Encouraging activity of bicalutamide and everolimus in castration-resistant prostate cancer (CRPC): Early results from a phase I/II clinical trial Cancer Research. 70: 3720-3720. DOI: 10.1158/1538-7445.Am10-3720 |
0.439 |
|
| 2010 |
Wang S, He M, Li T, White RdV, Lara PN, Gandara D, Mack PC, Turteltaub K, Henderson PT, Pan C. Abstract 3522: A Phase 0 microdosing trial to identify chemoresistance: From bench to bedside Cancer Research. 70: 3522-3522. DOI: 10.1158/1538-7445.Am10-3522 |
0.422 |
|
| 2008 |
Pan C, Hussey M, Lara PN, Mack PC, Nagle R, Dutcher JP, Samlowski WE, Clark J, Gordon MS, Crawford ED. Encouraging survival with erlotinib in advanced papillary renal cell carcinoma (pRCC): Final results from Southwest Oncology Group study 0317. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 5051. PMID 27948885 DOI: 10.1200/Jco.2008.26.15_Suppl.5051 |
0.306 |
|
| 2007 |
Chee KG, Longmate J, Quinn DI, Chatta G, Pinski J, Twardowski P, Pan CX, Cambio A, Evans CP, Gandara DR, Lara PN. The AKT inhibitor perifosine in biochemically recurrent prostate cancer: A phase II California/Pittsburgh cancer consortium trial Clinical Genitourinary Cancer. 5: 433-437. PMID 18272025 DOI: 10.3816/Cgc.2007.N.031 |
0.458 |
|
| 2007 |
Vinall RL, Hwa K, Ghosh PM, Pan C, Lara PN, White RWd. Combination treatment of prostate cancer cell lines with bioactive soy isoflavones and perifosine causes increased growth arrest and/or apoptosis. Clinical Cancer Research. 13: 6204-6216. PMID 17947488 DOI: 10.1158/1078-0432.Ccr-07-0600 |
0.426 |
|
| 2007 |
Aina OH, Liu R, Sutcliffe JL, Marik J, Pan CX, Lam KS. From combinatorial chemistry to cancer-targeting peptides. Molecular Pharmaceutics. 4: 631-51. PMID 17880166 DOI: 10.1021/Mp700073Y |
0.374 |
|
| 2007 |
Nelson EC, Evans CP, Pan CX, Lara PN. Prostate cancer and markers of bone metabolism: Diagnostic, prognostic, and therapeutic implications World Journal of Urology. 25: 393-399. PMID 17562051 DOI: 10.1007/S00345-007-0186-3 |
0.353 |
|
| 2007 |
Pan CX, Zhu W, Cheng L. Implications of cancer stem cells in the treatment of cancer. Future Oncology (London, England). 2: 723-31. PMID 17155899 DOI: 10.2217/14796694.2.6.723 |
0.402 |
|
| 2007 |
Pan C, Hussey M, Lara P, Mack PC, Nagle RB, Dutcher J, Samlowski W, Clark J, Crawford ED, Gordon MS. Phase II trial of the epidermal growth factor receptor (EGFR) inhibitor erlotinib (E) in patients (pts) with advanced papillary renal cell carcinoma (pRCC)—SWOG S0317 Journal of Clinical Oncology. 25: 15516-15516. DOI: 10.1200/Jco.2007.25.18_Suppl.15516 |
0.312 |
|
| 2007 |
Vinall RL, Hwa K, Pan C, Ghosh P, Lara PN, White RWd. Dual AKT inhibition with perifosine and GCP enhances apoptosis in prostate cancer: Clinical implications Journal of Clinical Oncology. 25: 14096-14096. DOI: 10.1200/Jco.2007.25.18_Suppl.14096 |
0.399 |
|
| 2006 |
Pan C, Zhang H, Lara PN, Cheng L. Small-cell carcinoma of the urinary bladder: diagnosis and management. Expert Review of Anticancer Therapy. 6: 1707-1713. PMID 17181484 DOI: 10.1586/14737140.6.12.1707 |
0.395 |
|
| 2005 |
Cheng L, Poulos CK, Pan CX, Jones TD, Daggy JK, Eble JN, Koch MO. Preoperative prediction of small volume cancer (less than 0.5 ml) in radical prostatectomy specimens. The Journal of Urology. 174: 898-902. PMID 16093983 DOI: 10.1097/01.Ju.0000169134.28610.66 |
0.391 |
|
| 2005 |
Pan CX, Loehrer P, Seitz D, Helft P, Juliar B, Ansari R, Pletcher W, Vinson J, Cheng L, Sweeney C. A phase II trial of irinotecan, 5-fluorouracil and leucovorin combined with celecoxib and glutamine as first-line therapy for advanced colorectal cancer. Oncology. 69: 63-70. PMID 16088234 DOI: 10.1159/000087302 |
0.305 |
|
| 2004 |
Cheng L, Pan CX, Zhang JT, Zhang S, Kinch MS, Li L, Baldridge LA, Wade C, Hu Z, Koch MO, Ulbright TM, Eble JN. Loss of 14-3-3sigma in prostate cancer and its precursors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 10: 3064-8. PMID 15131044 DOI: 10.1158/1078-0432.Ccr-03-0652 |
0.361 |
|
| 2004 |
Pan CX, Kinch MS, Kiener PA, Langermann S, Serrero G, Sun L, Corvera J, Sweeney CJ, Li L, Zhang S, Baldridge LA, Jones TD, Koch MO, Ulbright TM, Eble JN, et al. PC cell-derived growth factor expression in prostatic intraepithelial neoplasia and prostatic adenocarcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 10: 1333-7. PMID 14977833 DOI: 10.1158/1078-0432.Ccr-1123-03 |
0.376 |
|
| 2003 |
Zeng G, Hu Z, Kinch MS, Pan CX, Flockhart DA, Kao C, Gardner TA, Zhang S, Li L, Baldridge LA, Koch MO, Ulbright TM, Eble JN, Cheng L. High-level expression of EphA2 receptor tyrosine kinase in prostatic intraepithelial neoplasia. The American Journal of Pathology. 163: 2271-6. PMID 14633601 DOI: 10.1016/S0002-9440(10)63584-5 |
0.356 |
|
| 1999 |
Pan CX, Koeneman KS. A novel tumor-specific gene therapy for bladder cancer. Medical Hypotheses. 53: 130-5. PMID 10532707 DOI: 10.1054/Mehy.1998.0731 |
0.352 |
|
| 1998 |
Koeneman KS, Pan CX, Jin JK, Pyle JM, Flanigan RC, Shankey TV, Diaz MO. Telomerase activity, telomere length, and DNA ploidy in prostatic intraepithelial neoplasia (PIN). The Journal of Urology. 160: 1533-9. PMID 9751408 DOI: 10.1016/S0022-5347(01)62608-9 |
0.547 |
|
| 1997 |
Pan C, Xue BH, Ellis TM, Peace DJ, Díaz MO. Changes in telomerase activity and telomere length during human T lymphocyte senescence. Experimental Cell Research. 231: 346-53. PMID 9087176 DOI: 10.1006/Excr.1997.3475 |
0.536 |
|
| Show low-probability matches. |